Radiopharm Theranostics Ltd (RADX) Form 6-K — Oct 27, 2026
Radiopharm Theranostics filed a 6-K containing its Notice of Annual General Meeting, to be held virtually on 25 November 2026. Shareholders will vote on four resolutions: adoption of the Remuneration Report, election of director Bruce Goodwin, renewal of the Omnibus Incentive Plan, and approval of 10% additional placement capacity under ASX Listing Rule 7.1A. The Listing Rule 7.1A approval would let the company issue up to 10% of its capital (about 467 million shares) over 12 months without further shareholder approval, on top of its 15% Listing Rule 7.1 capacity — combined 25% dilution capacity.
Key figures
- Shares Outstanding
- 4710882790
- Agm date
- 25 November 2026
- Placement capacity percent
- 10% under Listing Rule 7.1A plus 15% under Listing Rule 7.1
- August 2026 placement price
- $0.015 (21.1% discount to last close of A$0.019)
- August 2026 placement shares
- 350457139
- August 2026 placement proceeds
- $5,256,857
- Shares under rule 7 1 capacity
- 618729503
- Shares under rule 7 1 A capacity
- 467123802
- Max securities under incentive plan 3yr
- 471088279
- Securities issued under incentive plan since 2025
- 241988666
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.